Stock listing

ASX:PAB Patrys Limited Share Price

Home listing (ASX) of Patrys Limited

Follow Patrys Limited into a list and get an email when it puts out news.

Share price · ASX:PAB

$0.022 AUD -0.001 (-4.3%)

Close on Nov 20, 2026

Past year -40.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.022 – $0.022 AUDNov 20, 2026
Volume
207 sharesNov 20, 2026
Market cap
$7.50M AUDAt the close on Nov 20, 2026 · price × 340.7M shares outstanding
52-week range
$0.020 – $0.052 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$9,892 AUDMedian day 123,867 shares · 4 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Patrys Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:PAB · Home$0.022 AUD-0.001 (-4.3%)207$0.022$0.022$0.022$0.023Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:PAB · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.022-0.001-4.3%$0.022$0.022$0.022207
$0.0230.0000.0%$0.023$0.023$0.023102,990
$0.0230.0000.0%$0.023$0.023$0.02367,179
$0.0230.0000.0%$0.023$0.023$0.0239,493
$0.0230.0000.0%$0.024$0.024$0.023239,300
$0.0230.0000.0%$0.022$0.023$0.02296,017
$0.023-0.001-4.2%$0.022$0.023$0.02246,321
$0.024+0.004+20.0%$0.020$0.024$0.020353,610
$0.020-0.002-9.1%$0.021$0.021$0.0201,081,082
$0.0220.0000.0%$0.022$0.022$0.0220
$0.022-0.001-4.3%$0.023$0.023$0.020370,603
$0.023-0.002-8.0%$0.025$0.025$0.02364,169
$0.0250.0000.0%$0.025$0.025$0.025400
$0.025+0.001+4.2%$0.025$0.025$0.0255,052
$0.024-0.001-4.0%$0.024$0.024$0.0241,707
$0.0250.0000.0%$0.026$0.026$0.025327,462
$0.025-0.001-3.8%$0.026$0.026$0.025644,150
$0.026-0.001-3.7%$0.027$0.027$0.02636,610
$0.0270.0000.0%$0.027$0.027$0.027156,199
$0.027-0.001-3.6%$0.028$0.029$0.027574,454
$0.0280.0000.0%$0.028$0.028$0.0287,385
$0.028+0.001+3.7%$0.029$0.029$0.02862,965
$0.0270.0000.0%$0.027$0.027$0.027108,508
$0.0270.0000.0%$0.027$0.027$0.0270
$0.027-0.002-6.9%$0.028$0.028$0.027553,613
$0.029-0.001-3.3%$0.029$0.029$0.02934,714
$0.0300.0000.0%$0.030$0.030$0.03016,667
$0.0300.0000.0%$0.030$0.030$0.030137,470
$0.0300.0000.0%$0.030$0.031$0.0301,394,568
$0.030-0.002-6.3%$0.031$0.031$0.030990,343
$0.032+0.002+6.7%$0.031$0.032$0.03069,472
$0.030-0.001-3.2%$0.030$0.030$0.0301,567,603
$0.031+0.001+3.3%$0.031$0.031$0.03121,770
$0.030-0.002-6.3%$0.032$0.032$0.030290,811
$0.032-0.001-3.0%$0.032$0.032$0.03210,000
$0.033+0.002+6.5%$0.033$0.033$0.033141,874
$0.031-0.002-6.1%$0.030$0.032$0.030110,373
$0.033+0.003+10.0%$0.030$0.033$0.030154,596
$0.030-0.001-3.2%$0.031$0.031$0.030517,830
$0.031-0.001-3.1%$0.031$0.031$0.03110,065
$0.0320.0000.0%$0.032$0.032$0.032103,846
$0.032-0.001-3.0%$0.033$0.034$0.032242,965
$0.0330.0000.0%$0.033$0.033$0.03330,299
$0.033-0.001-2.9%$0.033$0.033$0.03379,599
$0.0340.0000.0%$0.034$0.034$0.034207,276
$0.0340.0000.0%$0.033$0.034$0.0331,181,719
$0.034-0.001-2.9%$0.034$0.034$0.033535,087
$0.035+0.001+2.9%$0.034$0.035$0.0312,077,129
$0.034+0.003+9.7%$0.031$0.035$0.0311,332,686
$0.031-0.001-3.1%$0.031$0.032$0.031137,360
$0.0320.0000.0%$0.032$0.033$0.032493,958
$0.0320.0000.0%$0.032$0.032$0.032753,479
$0.032+0.002+6.7%$0.031$0.032$0.031446,329
$0.0300.0000.0%$0.030$0.030$0.0300
$0.0300.0000.0%$0.030$0.031$0.030620,799
$0.0300.0000.0%$0.030$0.030$0.030969,792
$0.030-0.001-3.2%$0.030$0.030$0.030582,118
$0.031+0.001+3.3%$0.030$0.031$0.03017,733
$0.030-0.001-3.2%$0.030$0.030$0.030102,429
$0.031+0.001+3.3%$0.031$0.032$0.030597,129
$0.0300.0000.0%$0.030$0.030$0.0300
$0.030-0.001-3.2%$0.031$0.031$0.030522,879
$0.031-0.001-3.1%$0.032$0.032$0.03145,058
$0.032-0.001-3.0%$0.033$0.033$0.03235,294
$0.0330.0000.0%$0.033$0.033$0.033250
$0.033+0.001+3.1%$0.032$0.033$0.032238,219

Splits

2 splits since 2013 · ASX:PAB · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
96-for-89Split
Ticker
ASX:PAB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
ASX
Currency
AUD

What changed lately

Latest news

Change of Auditor

Nov 11, 2026

Closed $0.023 (0.0%) on Nov 12, 2026

Change in substantial holding

Nov 9, 2026

Closed $0.024 (+20.0%) on Nov 10, 2026

Change of Director's Interest Notice x2

Nov 9, 2026

Closed $0.024 (+20.0%) on Nov 10, 2026

Cleansing Notice

Nov 9, 2026

Closed $0.024 (+20.0%) on Nov 10, 2026

Application for quotation of securities - PAB

Nov 9, 2026

Closed $0.024 (+20.0%) on Nov 10, 2026

Notice of Annual General Meeting/Proxy Form

Oct 29, 2026

Closed $0.024 (-4.0%) on Oct 30, 2026

Investor Presentation

Oct 12, 2026

Closed $0.03 (0.0%) on Oct 13, 2026

All Patrys Limited news

Patrys Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
38 in the last 12 months · 191 in all · newest Nov 11, 2026 · oldest 2016
Decks
46 decks · latest Oct 13, 2026

Where Patrys Limited is listed

ListingExchangeCountryCurrency
ASX:PAB · Home listing · This pageASXAustraliaAUD
OTC:PABAFOTCUnited StatesUSD

Cash and shares

Oct 2026 deck · Patrys — Investor Presentation (October 2026)

Cash
$3.36 million
Shares outstanding
674,845,324

The slide these figures come from

Valuation

EV/sales 8.2× against a median of −1.5×: 3rd lowest of 4 Biotechnology companies shown. Statements: Year to Jun 30, 2025 · price Nov 20, 2026

Enterprise value
$6.75M AUD
P/E
Loss
EV/sales
8.2×
EV/EBITDA
Negative EBITDA
Price/book
10.2×
Gross margin
100.0%
Operating margin
−327.0%
Net margin
−363.7%
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Patrys Limited · ASX:PABUS$4.96MUS$4.47Mn/a8.2×n/a10.2×−363.7%0.0×n/a
CNS Pharmaceuticals, Inc. · NASDAQ:CNSPUS$5.25M−US$11.96Mn/an/an/a0.3×n/a0.0×0.74
Soligenix, Inc. · NASDAQ:SNGXUS$5.14M−US$3.61Mn/an/an/a0.8×n/a0.0×1.76
Rakovina Therapeutics Inc · TSXV:RKVUS$5.10MUS$7.20Mn/an/an/an/an/an/a-0.43
StimCell Energetics Inc. · OTC:STMEUS$5.10MUS$5.09Mn/an/an/an/an/an/a0.99
Longeveron Inc. · NASDAQ:LGVNUS$5.05M−US$1.78Mn/a−1.5×n/a1.1×n/a0.1×1.55
Oncodesign Precision Medicine S.A. · EURONEXT:ALOPMUS$5.04MUS$8.61M0.8×30.0×0.9×1.2×n/a1.6×n/a
Invex Therapeutics Ltd. · ASX:IXCUS$4.86MUS$2.20Mn/an/an/a1.9×n/a0.0×n/a
Can-Fite BioPharma Ltd. · TASE:CANFUS$4.86M−US$2.14Mn/a−5.3×n/a1.0×n/a0.0×n/a
Zenith Capital Corporation · OTC:ZHCLFUS$4.83Mn/an/an/an/an/an/an/a0.06
NFL Biosciences SA · EURONEXT:ALNFLUS$4.71MUS$5.36Mn/an/an/an/an/an/an/a
Median of the othersUS$5.05MUS$2.20M0.8×−1.5×0.9×1.0×0.0×0.87

Team and board

Officers

OfficerRole
Samantha SouthChief Executive Officer

Board

DirectorRole
Peter ChristieNon-Executive Chairman
Anton UvarovNon-Executive Director
Brian LeedmanNon-Executive Director
Dino CercarelliNon-Executive Director
Leanne KiteNon-Executive Director

Events

QuarterResultsShare move
Q4 2025Sep 5, 2025+50.0%
Q2 2025Feb 21, 2025+17.9%
Q2 2023Feb 24, 2023 · Before open0.0%
Q4 2022Aug 30, 2022 · After close+3.8%
Q2 2022Feb 24, 20220.0%
Q4 2021Aug 25, 2021+22.1%
Q2 2021Feb 19, 20210.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck17 slidesOct 13, 2026
Investor Presentation (July 2026)Investor deck19 slidesJul 27, 2026
Investor Presentation (March 2026)Investor deck14 slidesMar 31, 2026
Investor Presentation (January 2026)Investor deck21 slidesJan 28, 2026
Shareholder Meeting (November 2024)Shareholder meeting18 slidesNov 22, 2024
Investor Presentation (November 2023)Investor deck26 slidesNov 20, 2023
Shareholder Meeting (November 2023)Shareholder meeting24 slidesNov 15, 2023
Investor Presentation (January 2023)Investor deck27 slidesJan 25, 2023
Investor Presentation (November 2022)Investor deck27 slidesNov 24, 2022
ShareCafe Small Cap "Hidden Gems" Webinar (November 2022)Conference19 slidesNov 24, 2022
All 46 decks
DeckKindSlidesDate
Shareholder Meeting (November 2022)Shareholder meeting25 slidesNov 16, 2022
Investor Presentation (September 2022)Investor deck25 slidesSep 1, 2022
Shareholder Meeting (November 2021)Shareholder meeting23 slidesNov 5, 2021
Investor Presentation (November 2021)Investor deck25 slidesNovember 2021
Investor Presentation (November 2021)Investor deck33 slidesNov 1, 2021
Investor Presentation (September 2021)Investor deck21 slidesSep 28, 2021
Investor Presentation (May 2021)Investor deck25 slidesMay 2021
Shareholder Meeting (November 2020)Shareholder meeting19 slidesNov 19, 2020
Investor Presentation (November 2020)Investor deck33 slidesNov 5, 2020
Investor Presentation (June 2020)Investor deck35 slidesJun 18, 2020
Shareholder Meeting (November 2019)Shareholder meeting22 slidesNov 21, 2019
Investor Presentation (July 2019)Investor deck27 slidesJul 24, 2019
Shareholder Meeting (November 2018)Shareholder meeting26 slidesNov 22, 2018
Shareholder Meeting (November 2017)Shareholder meeting26 slidesNov 23, 2017
Shareholder Meeting (November 2016)Shareholder meeting18 slidesNov 24, 2016
Shareholder Meeting (November 2015)Shareholder meeting12 slidesNov 11, 2015
Shareholder Meeting (November 2014)Shareholder meeting11 slidesNov 12, 2014
Investor Presentation (September 2014)Investor deck24 slidesSep 18, 2014
Shareholder Meeting (October 2013)Shareholder meeting22 slidesOct 23, 2013
Investor Presentation (November 2012)Investor deck29 slidesNov 27, 2012
Shareholder Meeting (October 2012)Shareholder meeting20 slidesOct 31, 2012
Non-Deal Roadshow (April 2012)Roadshow47 slidesApr 12, 2012
Shareholder Meeting (November 2011)Shareholder meeting15 slidesNov 30, 2011
Investor Presentation (October 2011)Investor deck20 slidesOct 10, 2011
Investor Presentation (June 2011)Investor deck19 slidesJun 2, 2011
Investor Presentation (March 2011)Investor deck26 slidesMar 9, 2011
Shareholder Meeting (October 2010)Shareholder meeting18 slidesOct 29, 2010
Investor Presentation (October 2010)Investor deck18 slidesOct 15, 2010
Shareholder Meeting (November 2009)Shareholder meeting16 slidesNov 27, 2009
AusBiotech Life Sciences Investment Summit 2009Conference7 slidesOct 27, 2009
Investor Presentation (September 2009)Investor deck25 slidesSep 22, 2009
Corporate Update (July 2009)Corporate update14 slidesJul 1, 2009
Shareholder Meeting (November 2008)Shareholder meeting29 slidesNov 27, 2008
6th Annual Australian Biotechnology Summit (July 2008)Conference23 slidesJul 31, 2008
Excellence in Biotechnology 2008Conference19 slidesApr 21, 2008
Lodge Mid Cap Confab 2008Conference18 slidesApr 9, 2008

Open Decks

Financings

RaiseDateIn US dollars
Private placement of fully paid ordinary shares
Announced: about A$3.2M · A$0.024 a share · Warrants at A$0.048 · Templar Corporate Pty Ltd
Dealers: Templar Corporate Pty Ltd (lead)
Insiders: Directors intend to participate to raise an additional A$160,000, subject to shareholder approval
Use of proceeds: Phase 1A clinical trial, drug manufacturing, pre-IND FDA preparation, intellectual property and working capital
Apr 20, 2026US$2.29M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue828.5K1.39M2.85M27.5K27.5K27.5K844.4K520.5K53.3K275.0K
Cost of revenue47.0K47.0K-3.31M-1.31M-745.3K0-478.5K-592.7K
Gross profit828.5K1.39M2.80M3.33M1.34M772.8K844.4K520.5K531.7K867.7K
Research and development1.75M3.07M7.52M8.09M2.86M1.37M1.69M1.31M1.27M1.04M
Selling, general and administrative1.78M1.86M2.39M2.03M2.54M2.15M2.57M1.71M1.13M954.8K
Operating income-2.71M-3.54M-9.86M-11.4M-5.86M-3.49M-3.41M-2.50M-2.36M-1.72M
Depreciation and amortization49.3K47.0K47.0K47.5K48.6K47.8K48.3K47.8K47.5K20.1K
EBITDA-2.66M-3.49M-9.81M-11.3M-5.81M-3.45M-3.36M-2.45M-2.31M-1.70M
Interest expense8.10K000000
Income before tax-3.01M-4.82M-9.84M-11.6M-5.74M-3.37M-411.3K-2.50M-1.47M-1.58M
Income tax-807.3K-1.29M-2.78M-4.79M-1.67M-623.2K-644.3K-455.2K-410.2K-502.5K
Net income-3.01M-3.54M-7.06M-6.78M-4.06M-2.75M-411.3K-2.50M-1.06M-1.08M
Earnings per share, basic-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents742.4K2.24M3.05M7.82M6.92M3.98M6.47M4.61M1.91M3.22M
Short-term investments01.00M2.00M4.00M4.00M2.00M650.0K
Receivables825.3K1.34M2.84M3.41M1.28M680.0K25.2K25.2K25.2K259.3K
Inventory1-259.3K
Current assets1.74M3.81M7.13M13.5M12.4M4.84M7.35M7.35M2.49M3.54M
Property, plant and equipment04.30K1.67K3.66K3.92K3.60K6.38K5.63K4.34K5.87K
Total assets1.74M4.16M7.52M14.0M12.9M5.38M7.93M7.97M3.16M4.26M
Accounts payable136.0K238.4K290.4K161.7K297.9K78.0K199.0K220.4K65.3K35.5K
Current liabilities1.01M688.7K686.9K542.8K849.9K473.4K621.1K660.6K480.0K595.0K
Total liabilities1.01M691.4K686.9K542.8K849.9K498.4K637.4K681.8K495.5K620.3K
Shareholders' equity732.9K3.47M6.84M13.4M12.0M4.88M7.30M7.29M2.66M3.64M
Shares outstanding2.58B2.06B2.06B1.96B1.62B1.08B1.08B941.2M780.4M743.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-1.77M-1.82M-5.78M-8.68M-3.88M-2.50M-129.2K-2.09M-1.28M-1.53M
Capital spending-2-3.24K0-2.29K-3.89K-3.89K-4.06K-4.13K-2.77K-4.90K
Free cash flow-1.77M-1.82M-5.78M-8.68M-3.88M-2.50M-133.2K-2.09M-1.28M-1.54M
Cash from investing01.01M1.00M1.99M-4.00M-4.00M2.00M-2.00M-2.77K64.1K
Cash from financing276.0K4.29K6.45K7.56M11.1M2.50M1.80K6.82M6.82M6.82M
Share buybacks-32.4K4.29K6.45K-345.2K-636.2K-636.2K1.80K-199.0K
Change in cash-1.50M-804.9K-4.77M901.2K2.94M-2.49M1.87M2.69M-1.30M-1.43M

Open Financials

Filings

FilingDateTypeFiled with
Change of AuditorNov 11, 2026Management or board changeASX
Change in substantial holdingNov 9, 2026Ownership change noticeASX
Change of Director's Interest Notice x2Nov 9, 2026Ownership change noticeASX
Cleansing NoticeNov 9, 2026FinancingASX
Application for quotation of securities - PABNov 9, 2026FinancingASX
Letter to Shareholders - Annual General MeetingOct 29, 2026Meeting noticeASX
Notice of Annual General Meeting/Proxy FormOct 29, 2026Meeting noticeASX
Appendix 4C - Quarterly - 30 September 2026Oct 28, 2026Quarterly reportASX
Appendix 4C - Quarterly - 30 September 2026Oct 28, 2026Quarterly reportASX
RLS-2202 Phase 1a Trial Advances to Cohort 2Oct 21, 2026Other filingsASX
All 182 filings
FilingDateTypeFiled with
RLS-2202 Phase 1a Trial Advances to Cohort 2Oct 21, 2026Other filingsASX
Investor PresentationOct 12, 2026Other filingsASX
Investor WebinarOct 5, 2026Other filingsASX
Date of AGM and Closing Date for Director NominationsOct 5, 2026Meeting noticeASX
Notification of cessation of securities - PABSep 30, 2026FinancingASX
Patrys Completes Cohort 1 Dosing and Follow-UpSep 28, 2026Operations updateASX
Appendix 4E Variance ReportSep 28, 2026ResultsASX
Annual Report - 30 June 2025Sep 28, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementSep 28, 2026Other filingsASX
First Participants Dosed in RLS-2202 Phase 1A Clinical TrialSep 22, 2026Other filingsASX
PAB Establishes Clinical Advisory CommitteeSep 16, 2026Operations updateASX
Appendix 4E - Preliminary Final ReportAug 31, 2026ResultsASX
Ethics Approval Secured for Phase 1A Clinical TrialAug 27, 2026Other filingsASX
Investor Presentation - TechKnow Invest RoadshowJul 26, 2026Other filingsASX
Appendix 4C - Quarterly - 30 June 2026Jul 21, 2026Quarterly reportASX
Patrys Secures 50% Revenue Share in IP CommercialisationJul 12, 2026Acquisition or disposalASX
Patrys advances RLS-2202 toward Phase 1 Clinical TrialMay 19, 2026Other filingsASX
Appendix 4C - Quarterly - 31 March 2026Apr 29, 2026Quarterly reportASX
$3.2 million Placement to Advance Clinical TrialsApr 19, 2026FinancingASX
Investor Presentation - Broker Meets BiotechMar 30, 2026Other filingsASX
RLS-2201 Manufacturing and Regulatory Pathway InitiatedMar 10, 2026Operations updateASX
Appendix 4D - Half Year Accounts - 31 December 2025Feb 26, 2026Interim reportASX
Appointment of Chief Executive OfficerFeb 11, 2026Management or board changeASX
Appendix 4C - Quarterly - 31 December 2025Jan 29, 2026Quarterly reportASX
Investor PresentationJan 27, 2026Acquisition or disposalASX
Completion of Acquisition and Board AppointmentsJan 27, 2026Acquisition or disposalASX
Pipeline Expanded with Proprietary Injectable AntipsychoticNov 25, 2025Acquisition or disposalASX
Trading HaltNov 23, 2025Trading halt or suspensionASX
Appendix 4C - Quarterly - 30 September 2025Oct 29, 2025Quarterly reportASX
Patrys Receives R&D Tax Incentive RefundOct 29, 2025FinancingASX
Notice of Annual General Meeting/Proxy FormSep 7, 2025Meeting noticeASX
Appendix 4E - Preliminary Final ReportAug 29, 2025Annual reportASX
Appendix 4C - Quarterly - 30 June 2025Jul 29, 2025Quarterly reportASX
Entitlement Offer ProspectusJul 23, 2025Offer documentASX
Non-Renounceable Entitlement OfferJul 23, 2025Offer documentASX
Deed of Release entered into with CEOJun 16, 2025Management or board changeASX
Successful Placement and Board ChangesJun 10, 2025FinancingASX
Reinstatement to Official QuotationJun 10, 2025Trading halt or suspensionASX
Suspension from QuotationJun 3, 2025Trading halt or suspensionASX
Appendix 4C - Quarterly - 31 March 2025Apr 30, 2025Quarterly reportASX
Appendix 4D - Half Year Accounts - 31 December 2024Feb 21, 2025Interim reportASX
Appendix 4C - Quarterly - 31 December 2024Jan 29, 2025Quarterly reportASX
Appendix 4C - Quarterly - 30 September 2024Oct 29, 2024Quarterly reportASX
PAT-DX1 clinical development updateOct 1, 2024Other filingsASX
PAT-DX1 GMP specification testing updateSep 19, 2024Other filingsASX
Appendix 4E and 2024 Annual ReportAug 23, 2024Annual reportASX
Further update on PAT-DX1 GMP manufacturing runJul 28, 2024Other filingsASX
Appendix 4C - Quarterly - 30 June 2024Jul 23, 2024Quarterly reportASX
Update on GMP manufacturing run of PAT-DX1Jun 30, 2024Other filingsASX
Appendix 4C - Quarterly - 31 March 2024Apr 29, 2024Quarterly reportASX
Positive preclinical data for deoxymabs in vasculitisApr 8, 2024Operations updateASX
Appendix 4D - Half Year Accounts - 31 December 2023Feb 23, 2024Interim reportASX
Appendix 4C - Quarterly - 31 December 2023Jan 22, 2024Quarterly reportASX
GMP Production of PAT-DX1 Next QuarterDec 12, 2023Operations updateASX
Appendix 4C - Quarterly - 30 September 2023Oct 19, 2023Quarterly reportASX
Appendix 4E and 2023 Annual ReportAug 28, 2023Annual reportASX
Appendix 4C - Quarterly - 30 June 2023Jul 25, 2023Quarterly reportASX
PAT-DX1 GLP toxicology reports receivedMay 23, 2023Other filingsASX
Appendix 4C - Quarterly - 31 March 2023Apr 24, 2023Quarterly reportASX
Two new deoxymab patents granted in the USAApr 16, 2023Other filingsASX
Updated guidance for PAT-DX1 phase 1 clinical studyMar 30, 2023GuidanceASX
New PAT-DX3 data demonstrates synthetic lethalityMar 13, 2023Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2022Feb 24, 2023Interim reportASX
Appendix 4C - Quarterly - 31 December 2022Jan 30, 2023Quarterly reportASX
Response to ASX Price QueryDec 14, 2022Explanation requestASX
Appendix 4C - Quarterly - 30 September 2022Oct 27, 2022Quarterly reportASX
PAT DX3 Crosses Blood Brain Barrier in Healthy AnimalsOct 16, 2022Other filingsASX
Appendix 4E and 2022 Annual ReportAug 30, 2022Annual reportASX
PAT-DX1 From Engineering Run Meets all Specification TestsAug 29, 2022Other filingsASX
New Research Grant For Deoxymabs in Metastatic Breast CancerAug 26, 2022Other filingsASX
PAT-DX1/Radiation Combination Improves Brain Cancer SurvivalAug 9, 2022Other filingsASX
Appendix 4C - Quarterly - 30 June 2022Jul 27, 2022Quarterly reportASX
PAT-DX1 Engineering Run Successfully CompletedJul 3, 2022Other filingsASX
New Mechanism By Which PAT-DX1 May Reduce Cancer MetastasisJun 13, 2022Other filingsASX
CBCF funding to support deoxymab brain cancer developmentJun 3, 2022Other filingsASX
Appendix 4C - Quarterly - 31 March 2022Apr 28, 2022Quarterly reportASX
Stable Cell Line for Production of PAT-DX3 EstablishedFeb 27, 2022Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2021Feb 24, 2022Interim reportASX
Appendix 4C - Quarterly - 31 December 2021Jan 30, 2022Quarterly reportASX
PAT-DX1 engineering updateJan 23, 2022Other filingsASX
Rights Issue Results and Shortfall NotificationDec 2, 2021FinancingASX
Rights Issue Offer DocumentNov 8, 2021FinancingASX
$7.8M Capital RaisingOct 31, 2021FinancingASX
Appendix 4C - Quarterly - 30 September 2021Oct 19, 2021Quarterly reportASX
Patrys proof of concept ADC significantly increases survivalOct 17, 2021Other filingsASX
PAT-DX3 proof of concept as potential ADC targeting antibodySep 14, 2021Other filingsASX
Appendix 4E and 2021 Annual ReportAug 25, 2021Annual reportASX
Market Update - PAT-DX1 Clinical Trial PreparationAug 2, 2021Other filingsASX
Appendix 4C - Quarterly - 30 June 2021Jul 29, 2021Quarterly reportASX
PAT-DX1 Improves Survival in Model of Pancreatic CancerJul 25, 2021Other filingsASX
Full size deoxymab PAT-DX3 crosses the blood brain barrierJul 11, 2021Other filingsASX
Response to ASX QueryJun 23, 2021Explanation requestASX
Paper highlights PAT-DX1 as potential brain cancer treatmentJun 15, 2021Other filingsASX
Patrys receives R&D Tax Incentive refundJun 9, 2021Other filingsASX
Appendix 4C - Quarterly - 31 March 2021Apr 27, 2021Quarterly reportASX
New United States patent granted for Patrys deoxymab assetsMar 30, 2021Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2020Feb 19, 2021Interim reportASX
Patrys Successfully Establishes PAT-DX1 Stable Cell LineFeb 9, 2021Other filingsASX
Appendix 4C - Quarterly - 31 December 2020Jan 27, 2021Quarterly reportASX
$7.3M Capital RaisingNov 8, 2020FinancingASX
Investor Presentation - November 2020 - UpdatedNov 5, 2020Other filingsASX
Investor Presentation - November 2020Nov 4, 2020Other filingsASX
Appendix 4C - Quarterly - 30 September 2020Oct 25, 2020Quarterly reportASX
First patent granted for Deoxymab-nanoparticlesOct 5, 2020Other filingsASX
Patrys adds full human antibody to Deoxymab portfolioSep 27, 2020Other filingsASX
Appendix 4E and 2020 Annual ReportAug 24, 2020Annual reportASX
Appendix 4C - Quarterly - 30 June 2020Jul 30, 2020Quarterly reportASX
$4.29 Million Fully Underwritten Rights IssueJun 22, 2020FinancingASX
Investor Presentation - June 2020Jun 17, 2020Other filingsASX
Appendix 4C - Quarterly - 31 March 2020Apr 26, 2020Quarterly reportASX
PAT-DX1 mechanism for crossing blood brain barrier confirmedMar 15, 2020Other filingsASX
PAT-DX1-NP crosses BBB and targets tumoursMar 1, 2020Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2019Feb 24, 2020Interim reportASX
Appendix 4C - Quarterly - 31 December 2019Jan 29, 2020Quarterly reportASX
Appendix 4C - Quarterly - 30 September 2019Oct 28, 2019Quarterly reportASX
Appendix 4E and 2019 Annual ReportAug 22, 2019Annual reportASX
Appendix 4C - Quarterly - 30 June 2019Jul 29, 2019Quarterly reportASX
PAT-DX1 significantly improves survival in aggressive GBMJul 21, 2019Other filingsASX
Europe grants patent for Deoxymab 3E10Jul 17, 2019Other filingsASX
PAT-DX1 Reduces Brain Metastases, Enhances Radiation TherapyMay 29, 2019Other filingsASX
Appendix 4C - Quarterly - 31 March 2019Apr 23, 2019Quarterly reportASX
Market UpdateMar 29, 2019Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2018Feb 20, 2019Interim reportASX
Appendix 4C - Quarterly - 31 December 2018Jan 30, 2019Quarterly reportASX
PAT-DX1 Suppresses Breast Cancer Brain MetastasesDec 19, 2018Other filingsASX
Appendix 4C - Quarterly - 30 September 2018Oct 30, 2018Quarterly reportASX
Settlement of Manufacturing ClaimsOct 24, 2018Other filingsASX
PAT-DX1 Clinical Target Indications ConfirmedOct 4, 2018Other filingsASX
Patrys and WEHI Awarded GrantAug 28, 2018Other filingsASX
Appendix 4E and 2018 Annual ReportAug 24, 2018Annual reportASX
Patent Granted for Pre-clinical IgM Candidate PAT-LM1Aug 1, 2018Other filingsASX
Appendix 4C - Quarterly - 30 June 2018Jul 25, 2018Quarterly reportASX
Preliminary PAT-DX1 pharmacokineticsJul 5, 2018Other filingsASX
China and Japan both grant patents for Deoxymab 3E10Jul 3, 2018Other filingsASX
PAT-DX1 Targets and Kills Brain Cancer Stem CellsMay 30, 2018Other filingsASX
Patrys Increases Capital Raising to $4.6 millionMay 20, 2018FinancingASX
New Pre-Clinical Collaboration on PAT-DX1May 16, 2018Other filingsASX
Patrys Completes $3.5M PlacementMay 15, 2018FinancingASX
Appendix 4C - Quarterly - 31 March 2018Apr 26, 2018Quarterly reportASX
PAT-DX1 Improves Survival in Animal Model of GlioblastomaMar 18, 2018Other filingsASX
PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour SizeFeb 27, 2018Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2017Feb 23, 2018Interim reportASX
Appendix 4C - Quarterly - 31 December 2017Jan 31, 2018Quarterly reportASX
Publication and Patent Filing for Humanized Version of 3E10Jan 30, 2018Other filingsASX
PAT-DX1-NP Localizes to Lymph Node MetastasesJan 28, 2018Other filingsASX
Entitlement Offer BookletJan 14, 2018FinancingASX
PAT-DX1 is synergistic with PARP inhibitorDec 10, 2017Other filingsASX
Collaboration with WEHINov 15, 2017Other filingsASX
Appendix 4C - Quarterly - 30 September 2017Oct 27, 2017Quarterly reportASX
PAB and Garvan Institute of Medical Research Awarded GrantOct 15, 2017Other filingsASX
US Patent Granted for Preclinical Candidate PAT-LM1Oct 11, 2017Other filingsASX
PAT-DX1 Conjugated to Nanoparticles, Targets TumorsSep 17, 2017Other filingsASX
PAT-DX1 Active in Pre-clinical Cancer ModelsSep 13, 2017Other filingsASX
Appendix 4E and 2017 Annual ReportAug 29, 2017Annual reportASX
Appendix 4C - Quarterly - 30 June 2017Jul 26, 2017Quarterly reportASX
Patrys Deoxymab 3E10 patent granted in the U.S.Jul 12, 2017Other filingsASX
PAB Licences Deoxymab 3E10 - nanoparticle IP from YaleJun 12, 2017Other filingsASX
Finance UpdateApr 30, 2017Other filingsASX
Appendix 4C - Quarterly - 31 March 2017Apr 26, 2017Quarterly reportASX
Deoxymab 3E10 lead candidate confirmedApr 19, 2017Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2016Feb 22, 2017Interim reportASX
Appendix 4C - Quarterly - 31 December 2016Jan 17, 2017Quarterly reportASX
Appendix 4C - Quarterly - 30 September 2016Oct 28, 2016Quarterly reportASX
Appendix 4E and 2016 Annual ReportAug 30, 2016Annual reportASX
Appendix 4C - Quarterly - 30 June 2016Jul 27, 2016Quarterly reportASX
Appendix 4C - Quarterly - 31 March 2016Apr 20, 2016Quarterly reportASX
Publication on PAT-SM6 Combination TherapyApr 5, 2016Other filingsASX
Patrys Provides Update on CEO PositionMar 30, 2016Other filingsASX
Patrys Acquires Novel Assets from Yale UniversityMar 28, 2016Acquisition or disposalASX
Appendix 4D - Half Year Accounts - 31 December 2015Feb 24, 2016Interim reportASX
Appendix 4C - Quarterly - 31 December 2015Feb 11, 2016Quarterly reportASX
Appendix 4C - Quarterly - 30 September 2015Feb 10, 2016Quarterly reportASX

Open Filings

Cap table

Built by 6ix from Patrys Limited’s releases · as of Apr 20, 2026

Common shares
340,728,636
Fully diluted
340,728,636

Fully diluted

LineShares
Common shares340,728,636

Share count over time

CountShares
Nov 22, 2026340,728,636

Open Cap table

Shareholders

StakeStakeDateFiling
Leanne Kite6.87%Nov 9, 2026Substantial holder notice (ASX forms 603, 604, 605)

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anton UvarovNon-Executive Director · Since at least Nov 5, 2026
Brian LeedmanNon-Executive Director · Since at least Nov 5, 2026
Dino CercarelliNon-Executive Director · Since at least Nov 5, 2026
Leanne KiteNon-Executive Director · Since at least Nov 5, 2026
Peter ChristieNon-Executive Chairman · Since at least Nov 5, 2026
Samantha SouthChief Executive Officer · Since at least Oct 5, 2026

Open People

Log in to ask 6ix AI your own questions about Patrys Limited.